Cellular Biomedicine Group to Present at OneMedForum and BioTech Showcase in San Francisco
January 08 2015 - 8:00AM
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the
"Company"), a biomedicine firm engaged in the development of
effective treatments for degenerative and cancerous diseases, today
announced that management is scheduled to present at the 8th Annual
OneMedForum and the 7th Annual BioTech Showcase investor
conferences held in San Francisco, CA from January 12 – 14.
Management will also participate on a panel discussion titled
"Investing in the Immuno-Oncology Revolution" on January 14 at the
BioTech Showcase.
These major life science investor events bring together
investors, regenerative medicine and biopharmaceutical executives
from around the world to present and discuss the latest in
healthcare innovation. Over 2,000 executive-level delegates
representing qualified private and public equity investors,
industry analysts, bankers, pharmaceutical and biotechnology
industry executives as well as other industry professionals are
expected to attend. Company management will be available to
participate in one-on-one meetings with investors and strategic
partners during these conferences.
Event: OneMedForum Speaker:
Tony (Bizuo) Liu, Chief Financial Officer
Presentation: Corporate Overview
Location: San Francisco Marriot
Marquis, 780 Mission Street Date:
Tuesday January 13, 2015 Time:
1:40-2:00 PM (PST) Webcast: www.onemedforum.com
Event: BioTech Showcase
Speaker: William (Wei) Cao, BM, PhD, Chief
Executive Officer Panel Discussion: Investing in
the Immuno-Oncology Revolution
Location: San Francisco Parc 55
Wyndham Union Square Hotel Date:
Wednesday January 14, 2015 Time:
8:00-9:00 AM (PST)
Event: BioTech Showcase
Speaker: William (Wei) Cao, BM, PhD, Chief
Executive Officer Presentation: Corporate Overview
Location: San Francisco Parc 55 Wyndham Union
Square Hotel Date: Wednesday
January 14, 2015 Time:
10:30-11:00 AM (PST)
Management will deliver presentations and provide an overview of
the Company's business operations including 2014 milestone
accomplishments and revenue growth, and will discuss its 2015
projected growth plan and upcoming milestones. The Company's
proprietary therapies in various stages of research and development
include:
- ReJoinTM human adipose derived mesenchymal progenitor cell
(haMPC) therapy for Knee Osteoarthritis (KOA) and Cartilage Damage
(CD)
- CentrixTTM autologous central memory T-cell (Tcm) immunotherapy
for Cancer
- Immune function evaluation systems for the clinical studies of
Cancer
- Human adipose derived mesenchymal progenitor cell (haMPC)
therapy for Asthma
To arrange a meeting with management, please contact Vivian
Chen, Managing Director Investor Relations, Grayling at
vivian.chen@grayling.com.
To register for the events or for more information, please visit
the event websites:
http://www.onemedconferences.com/
http://www.ebdgroup.com/bts/program/index.php
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell
therapies for the treatment of certain degenerative diseases and
cancers. Our developmental stem cell, progenitor cell, and immune
cell projects are the result of research and development by
scientists and doctors from China and the United States. Our
flagship GMP facility, consisting of eight independent cell
production lines, is designed, certified and managed according to
U.S. standards. To learn more about CBMG, please visit:
www.cellbiomedgroup.com.
Forward-Looking Statements
Statements in this press release relating to plans, strategies,
trends, specific activities or investments, and other statements
that are not descriptions of historical facts may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include, but are not
limited to, risk factors inherent in doing business.
Forward-looking statements may be identified by terms such as
"may," "will," "expects," "plans," "intends," "estimates,"
"potential," or "continue," or similar terms or the negative of
these terms. Although CBMG believes the expectations reflected in
the forward-looking statements are reasonable, they cannot
guarantee that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to
update these forward-looking statements other than as required by
law.
CONTACT: Sarah Kelly
Director of Corporate Communications, CBMG
+1 650 566-5064
sarah.kelly@cellbiomedgroup.com
Vivian Chen
Managing Director Investor Relations, Grayling
+1 347 481-3711
vivian.chen@grayling.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Sep 2023 to Sep 2024